Vaxart Enters into Research Collaboration with Janssen to Evaluate Oral Universal Influenza Vaccine


SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Vaxart, Inc., (Vaxart), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it has entered into a research collaboration agreement with Janssen Vaccines & Prevention B.V. (Janssen) to evaluate Vaxart’s proprietary oral vaccine platform for the Janssen universal influenza vaccine program. Under the agreement Vaxart will produce an oral vaccine…

- Advertisement -